S&P 500   5,249.78 (+0.02%)
DOW   39,754.40 (-0.01%)
QQQ   444.67 (-0.04%)
AAPL   171.12 (-1.26%)
MSFT   420.91 (-0.12%)
META   490.60 (-0.66%)
GOOGL   150.77 (-0.07%)
AMZN   181.17 (+0.75%)
TSLA   175.88 (-2.20%)
NVDA   904.34 (+0.20%)
NIO   4.68 (+0.21%)
AMD   181.88 (+1.28%)
BABA   72.36 (+1.08%)
T   17.56 (+0.06%)
F   13.12 (+0.46%)
MU   117.93 (-1.02%)
CGC   8.95 (-6.28%)
GE   176.51 (-2.00%)
DIS   123.13 (+1.78%)
AMC   3.86 (-11.06%)
PFE   27.84 (+0.22%)
PYPL   66.73 (+0.24%)
XOM   115.37 (+0.35%)
S&P 500   5,249.78 (+0.02%)
DOW   39,754.40 (-0.01%)
QQQ   444.67 (-0.04%)
AAPL   171.12 (-1.26%)
MSFT   420.91 (-0.12%)
META   490.60 (-0.66%)
GOOGL   150.77 (-0.07%)
AMZN   181.17 (+0.75%)
TSLA   175.88 (-2.20%)
NVDA   904.34 (+0.20%)
NIO   4.68 (+0.21%)
AMD   181.88 (+1.28%)
BABA   72.36 (+1.08%)
T   17.56 (+0.06%)
F   13.12 (+0.46%)
MU   117.93 (-1.02%)
CGC   8.95 (-6.28%)
GE   176.51 (-2.00%)
DIS   123.13 (+1.78%)
AMC   3.86 (-11.06%)
PFE   27.84 (+0.22%)
PYPL   66.73 (+0.24%)
XOM   115.37 (+0.35%)
S&P 500   5,249.78 (+0.02%)
DOW   39,754.40 (-0.01%)
QQQ   444.67 (-0.04%)
AAPL   171.12 (-1.26%)
MSFT   420.91 (-0.12%)
META   490.60 (-0.66%)
GOOGL   150.77 (-0.07%)
AMZN   181.17 (+0.75%)
TSLA   175.88 (-2.20%)
NVDA   904.34 (+0.20%)
NIO   4.68 (+0.21%)
AMD   181.88 (+1.28%)
BABA   72.36 (+1.08%)
T   17.56 (+0.06%)
F   13.12 (+0.46%)
MU   117.93 (-1.02%)
CGC   8.95 (-6.28%)
GE   176.51 (-2.00%)
DIS   123.13 (+1.78%)
AMC   3.86 (-11.06%)
PFE   27.84 (+0.22%)
PYPL   66.73 (+0.24%)
XOM   115.37 (+0.35%)
S&P 500   5,249.78 (+0.02%)
DOW   39,754.40 (-0.01%)
QQQ   444.67 (-0.04%)
AAPL   171.12 (-1.26%)
MSFT   420.91 (-0.12%)
META   490.60 (-0.66%)
GOOGL   150.77 (-0.07%)
AMZN   181.17 (+0.75%)
TSLA   175.88 (-2.20%)
NVDA   904.34 (+0.20%)
NIO   4.68 (+0.21%)
AMD   181.88 (+1.28%)
BABA   72.36 (+1.08%)
T   17.56 (+0.06%)
F   13.12 (+0.46%)
MU   117.93 (-1.02%)
CGC   8.95 (-6.28%)
GE   176.51 (-2.00%)
DIS   123.13 (+1.78%)
AMC   3.86 (-11.06%)
PFE   27.84 (+0.22%)
PYPL   66.73 (+0.24%)
XOM   115.37 (+0.35%)
NASDAQ:DSGN

Design Therapeutics (DSGN) Stock Price, News & Analysis

$3.84
-0.07 (-1.79%)
(As of 10:09 AM ET)
Today's Range
$3.82
$3.94
50-Day Range
$2.27
$3.91
52-Week Range
$1.94
$8.47
Volume
19,885 shs
Average Volume
248,968 shs
Market Capitalization
$216.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Design Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
43.2% Upside
$5.50 Price Target
Short Interest
Healthy
6.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.89mentions of Design Therapeutics in the last 14 days
Based on 24 Articles This Week
Insider Trading
Acquiring Shares
$99,750 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.25) to ($1.39) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.19 out of 5 stars

Medical Sector

356th out of 939 stocks

Pharmaceutical Preparations Industry

160th out of 434 stocks

DSGN stock logo

About Design Therapeutics Stock (NASDAQ:DSGN)

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

DSGN Stock Price History

DSGN Stock News Headlines

The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Trending Stocks Sent To You In Real Time
Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar!
RBC Capital Reaffirms Their Hold Rating on Design Therapeutics (DSGN)
Design Therapeutics Inc (DSGN)
Earnings Preview For Design Therapeutics
DSGN Jul 2024 2.500 put
DSGN Apr 2024 7.500 put
SR ONE CAPITAL PARTNERS I, LP's Net Worth
Design Therapeutics Inc DSGN
See More Headlines
Receive DSGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Design Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DSGN
Fax
N/A
Employees
58
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.50
High Stock Price Target
$6.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+43.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
7 Analysts

Profitability

Net Income
$-66,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.96 per share

Miscellaneous

Free Float
40,789,000
Market Cap
$216.92 million
Optionable
Optionable
Beta
1.72
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

DSGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Design Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Design Therapeutics in the last year. There are currently 7 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" DSGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DSGN, but not buy additional shares or sell existing shares.
View DSGN analyst ratings
or view top-rated stocks.

What is Design Therapeutics' stock price target for 2024?

7 brokerages have issued twelve-month target prices for Design Therapeutics' stock. Their DSGN share price targets range from $4.00 to $6.00. On average, they expect the company's share price to reach $5.50 in the next year. This suggests a possible upside of 43.2% from the stock's current price.
View analysts price targets for DSGN
or view top-rated stocks among Wall Street analysts.

How have DSGN shares performed in 2024?

Design Therapeutics' stock was trading at $2.65 at the beginning of 2024. Since then, DSGN shares have increased by 44.9% and is now trading at $3.84.
View the best growth stocks for 2024 here
.

Are investors shorting Design Therapeutics?

Design Therapeutics saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 2,140,000 shares, a decrease of 24.9% from the February 29th total of 2,850,000 shares. Based on an average daily trading volume, of 259,700 shares, the days-to-cover ratio is currently 8.2 days. Approximately 6.5% of the shares of the company are sold short.
View Design Therapeutics' Short Interest
.

When is Design Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our DSGN earnings forecast
.

How were Design Therapeutics' earnings last quarter?

Design Therapeutics, Inc. (NASDAQ:DSGN) released its earnings results on Tuesday, November, 9th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.14) by $0.07.

What ETFs hold Design Therapeutics' stock?

ETFs with the largest weight of Design Therapeutics (NASDAQ:DSGN) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC).iShares Neuroscience and Healthcare ETF (IBRN).

When did Design Therapeutics IPO?

Design Therapeutics (DSGN) raised $228 million in an IPO on Friday, March 26th 2021. The company issued 12,000,000 shares at $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

Who are Design Therapeutics' major shareholders?

Design Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BML Capital Management LLC (1.84%), Goldman Sachs Group Inc. (1.83%), Goldman Sachs Group Inc. (1.83%), Vanguard Group Inc. (1.78%), Vanguard Group Inc. (1.78%) and Northern Trust Corp (0.67%). Insiders that own company stock include Arsani William, Deepa Prasad, Joao Md Siffert, John P Schmid, Rodney W Lappe, Simeon George, Sr One Capital Fund I Aggregat and Stella Xu.
View institutional ownership trends
.

How do I buy shares of Design Therapeutics?

Shares of DSGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DSGN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners